A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2021-05-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

NCT05800964

Advanced Solid Tumors

ACTIVE_NOT_RECRUITING PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

NCT04972981

Advanced Solid Tumors

COMPLETED PHASE1

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06418061

Unresectable Locally Advanced or Metastatic Solid Tumors

RECRUITING PHASE1

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

NCT07213817

Locally Advanced Solid Tumor Metastatic Solid Tumor

RECRUITING PHASE1/PHASE2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034

Advanced Solid Tumors MSI-H/dMMR Tumors Cutaneous Squamous Cell Carcinoma +15 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMC303

cohorts will receive ascending doses of AMC303 as intravenous infusion

Planned doses are:

0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg

Group Type EXPERIMENTAL

AMC303

Intervention Type DRUG

AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMC303

AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CD44v6 inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed.
2. Presence of a measurable tumour according to RECIST 1.1. criteria
3. At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC303.
4. Male or female patients, at least 18 years of age
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
6. Life expectancy \> 12 weeks.
7. Adequate haematological function defined as

* Absolute neutrophil count (ANC) \> 1,500 / µL
* Platelets \> 100,000 / µL
* Haemoglobin \> 9 g /dL.
8. Adequate renal function defined as

* Glomerular filtration rate (GFR) ≥ 50 ml/min according to local laboratory standard or
* Serum creatinine \< 1.5 mg / dL.
9. Adequate hepatic function defined as

* Total bilirubin \< 1.5x institutional upper limit of normal (ULN)
* AST, ALT ≤ 3x institutional ULN or \< 5x institutional ULN if known hepatic metastases
* Alkaline phosphatase \< 3x institutional ULN or \< 5x institutional ULN if known hepatic metastases.
10. Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination.
11. All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment.
12. Provision of signed Informed Consent prior to any study related procedure being performed

Exclusion Criteria

1. Receipt of any other investigational agent within 28 days prior to first administration of AMC303. Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC303.
2. Enrolment in another clinical study with an investigational drug
3. Presence of residual toxicities of CTCAE Grade \> 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions
4. Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements
5. Anticipation of major surgical procedures within first 4 weeks of first dose
6. Pregnancy or breast-feeding as determined by a serum pregnancy test (β-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant
7. Untreated acute infectious disease
8. Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease
9. Known chronic hepatitis B or C.
10. History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC303.
11. Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications
12. Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ
13. Legal incapacity or limited legal capacity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No